US20080267932A1 - Lactobacillus Rhamnosus with Body-Fat Reducing Activity and the Foods Containing Them - Google Patents

Lactobacillus Rhamnosus with Body-Fat Reducing Activity and the Foods Containing Them Download PDF

Info

Publication number
US20080267932A1
US20080267932A1 US11/659,368 US65936805A US2008267932A1 US 20080267932 A1 US20080267932 A1 US 20080267932A1 US 65936805 A US65936805 A US 65936805A US 2008267932 A1 US2008267932 A1 US 2008267932A1
Authority
US
United States
Prior art keywords
strain
lactobacillus rhamnosus
cla
lactobacillus
rhamnosus strain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/659,368
Other languages
English (en)
Inventor
Yeon-Hee Lee
Kyung-Soo Paek
Kenny Sohn
Tae-Jin Kim
Jee-Hoon Koh
Bum-Suk Park
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PL BIO CO Ltd
CJ CheilJedang Corp
Original Assignee
PL BIO CO Ltd
CJ CheilJedang Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PL BIO CO Ltd, CJ CheilJedang Corp filed Critical PL BIO CO Ltd
Assigned to PL BIO CO., LTD., CJ CORP. reassignment PL BIO CO., LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: KIM, TAE-JIN, KOH, JEE-HOON, LEE, YEON-HEE, PAEK, KYUNG-SOO, PARK, BUM-SUK, SOHN, KENNY
Assigned to CJ CHEILJEDANG CORP. reassignment CJ CHEILJEDANG CORP. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CJ CORP.
Publication of US20080267932A1 publication Critical patent/US20080267932A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus

Definitions

  • the present invention relates to Lactobacillus rhamnosus with body-fat reducing activity and foods containing them.
  • the present invention provides Lactobacillus strains with body-fat reducing activity.
  • the present invention also provides live organisms, killed organisms, broken cell wall fractions, a culture solution, a dried culture solution, a cultured extract containing CLA with a body-fat reducing effect, which result from the Lactobacillus strains of the present invention, and body-fat reducing functional foods and food additives containing them.
  • the present invention provides body-fat reducing functional foods and beverages using Lactobacillus strain with a body-fat reducing effect as a starter strain or additive.
  • the present invention provides a medicament with a body-fat reducing effect containing the Lactobacillus strains of the present invention.
  • the present invention provides conditions capable of maximizing a body-fat reducing effect when fermented foods are produced using the strains of the present invention.
  • a body-fat reducing mechanism is a reduction of adipose-cell number, a reduction of adipose-cell size, an ingestion reduction of energy and food, a production reduction of fat, an increase of energy consumption, lipolytic activity, an increase of lipid oxidation or like by inducing apoptosis of adipose cells (Chardigny J M, Hasselwander O, Genty M, Kraemer K, Ptock A, Sebedio J L. 2003, Effect of conjugated FA on feed intake, body composition, and liver FA in mice. Lipids. 38(9):895-902).
  • CLA (c9t11-octadecadienoic acid, t10c12-octadecadienoic acid) is formed through an isomerization of linoleic acid (LA, C18:2 cis9cis12). It has been known that CLA has an antioxidative effect, a cholesterol lowering effect, a growth promoting effect, and an anticancer-effect according to the location of double bonds. Recently, it has been known that CLA has body plasma lipids, a body-fat reducing effect, or like. It has been reported that CLA may be found in animal meats, fermented milk or like.
  • c9, t11-CLA of CLA isomers has a body-fat reducing effect.
  • c9t11-CLA and t10c12-CLA are most preferably produced in the same quantity.
  • Butyrivibrio fibrosolvents is the first found anaerobic microorganism that produces CLA, which is isolated from ruminants like a cow. It produces trans-11-Octadecenoic acid through 2 steps upon the biohydrogenation of LA. cis-9, trans-11-Octadecadienoic acid is produced by the action of linoleic acid isomerases, prior to hydrogenating the generated conjugated acid to produce trans-11-octadecenoic acid.
  • the present invention selected and identified a Korean-type Lactobacillus strain with a body-fat reducing effect that overproduced t10c12-CLA, confirmed characteristics of a probiotic, such as intestinal adaptation or like, in the strain, and found out conditions that the strain could maximally produce CLA and Lactobacillus strains with a body fat reducing effect by carrying out an animal experiment to confirm weight loss.
  • a probiotic such as intestinal adaptation or like
  • the present invention has been made in view of the above problems, and it is an object of the present invention to provide a strain that produces CLA.
  • the strain of the present invention is Lactobacillus rhamnosus Strain PL60 that was deposited as KCCM-10654P to Korean Culture Center of Microorganisms on May 9 h, 2005.
  • Another object of the present invention is to provide Lactobacillus strains capable of reducing body fat.
  • Still another object of the present invention is to prevent or treat various adult diseases by reducing body fat.
  • Another object of the present invention is to provide conditions that produce maximum CLA with a body-fat reducing effect.
  • Additional another object of the present invention is to provide a strain that has a body-fat reducing effect, good adhesion to the intestines, and strong tolerance to both acid and bile.
  • Another object of the present invention is to provide as a probiotic Lactobacillus strains that doesn't transfer an antibiotic resistance and is harmless.
  • Lactobacillus strains can be prepared in various compositions, preferably these compositions are compositional forms, such as capsules, tablets, powder etc and convenient forms capable of being added to various foods.
  • formulations can be prepared using pharmaceutically acceptable carriers, excipients, solvent or supplements by the known methods. These method and ingredients have been well known, and are in detail disclosed in standard texts and manuals, for example a publication (Remington. 1995. The Science and Practice of Pharmacy. Mack Publishing Co. Easton, Pa. 18042, USA), which is incorporated herein by reference.
  • Digestive Foods containing Lactobacillus strains may be prepared by the well-known method in the art.
  • Foods and beverages with a body-fat reducing effect may be prepared by the well-known method in the art using the strain as a starter strain or additive of fermented foods containing fermented milk products.
  • Fermented foods with a maximum body-fat reducing effect can be produced using conditions suggested herein.
  • the above and other objects can be accomplished by the provision of body-fat reducing functional foods.
  • Lactobacillus rhamnosus Strain PL60 KCCM-10654P capable of reducing body fat.
  • body-fat reducing functional foods containing Lactobacillus rhamnosus Strain PL60 KCCM-10654P in an amount of 1 ⁇ 10 6 -1 ⁇ 10 11 CFU/g in order to prevent and treat adult diseases using a body-fat reducing effect.
  • Lactobacillus rhamnosus Strain PL60 of the present invention has a body-fat reducing effect to be capable of preventing or treating diseases resulting from obesity.
  • dried Lactobacillus rhamnosus Strain PL60 and Lactobacillus rhamnosus Strain PL60 cultural filtrates, dried cultural filtrates of the present invention may be used as additives of various foods and beverages to be useful in preventing and treating body fat, hence can be used in preventing and treating all obesity-related diseases.
  • fermented foods using said Lactobacillus rhamnosus Strain PL60 of the present invention could prevent and treat obesity by a body-fat reducing effect.
  • Lactobacillus rhamnosus Strain PL60 must be primary-cultured in a medium containing LA in order to produce maximum CLA.
  • LA content is 100-1000 ppm
  • Tween-80 content is 1-0.1%
  • carbohydrate is preferably fructose, sucrose, and lactose, most preferably fructose, so that fermented foods using Lactobacillus rhamnosus Strain PL60 have a maximum body fat reducing effect.
  • FIG. 1 is a gas chromatogram identifying CLA generated by Lactobacillus rhamnosus Strain PL60.
  • FIG. 2 is a micrograph of Lactobacillus rhamnosus Strain PL60.
  • FIG. 3 shows the 16S rRNA sequence of Lactobacillus rhamnosus Strain PL60.
  • FIG. 4 is band patterns identifying Lactobacillus rhamnosus Strain PL60 using a multiplex PCR.
  • FIG. 5 shows the experimental results for an adaptation of Lactobacillus rhamnosus Strain PL60 to Caco-2 cells.
  • FIGS. 6 a and 6 b show the experimental results for an adhesion of Lactobacillus rhamnosus Strain PL60 to the human intestines.
  • FIG. 7 is band patterns illustrating PCR results of an isolated colony after orally administrating Lactobacillus rhamnosus Strain PL60 to people.
  • FIG. 8 shows the changes of the body weight of rats that took Lactobacillus rhamnosus Strain PL60.
  • FIG. 9 is a graph comparing the body weight of rats of each group after administrating Lactobacillus rhamnosus Strain PL60 on the 10 th week.
  • Lactobacillus strains that grew in a medium containing LA, a substrate of CLA were screened. And then, it was confirmed whether they expressed an isomerase enzyme, an enzyme involved in producing CLA.
  • Lactobacillus strains that grew in a medium containing linoleic acid (LA) were selected, of which CLA-producing Lactobacillus strains were screened.
  • CLA-producing strains may easily be screened from a large quantity of Lactobacillus strains by using an isomerase assay (Ogawa J, Matsumura K, Kishino S, Omura Y, and Shimizu S. 2001. Conjugated linoleic acid accumulation via 10-Hydroxy-12-octadecaenoic acid during microaerobic transformation of linoleic acid by Lactobacillus acidophilus. Appl. Envir. Microbiol. 67:1246-1252).
  • Lactobacillus strains that grew in a MRS medium containing 0.1% LA were primarily selected. And then, these Lactobacillus strains were twice subcultured in a MRS broth and cultured in a MRS broth containing 0.1% LA 10 mL for 2 days. The medium of 5 mL was centrifuged at 800 rpm for 10 minutes to collect cells, prior to washing the cells with a 0.1M potassium phosphate buffer solution (pH 7.0). Again, thereto a 0.1M potassium phosphate buffer solution (pH 7.0) 11.0 mL was added, followed by breaking and centrifuging the admixture every 3 minutes in a cold state using an ultrasonic breaker to obtain a crude enzyme solution. The crude enzyme solution was added to a substrate solution (LA 0.1 mL, 0.1M potassium phosphate buffer 2.7 mL, and 1,3-propanediol 0.2 mL) to measure an absorbance at 233 nm.
  • a substrate solution LA 0.1
  • CLA-producing Lactobacillus strains were screened out of more than 200 Lactobacillus strains using an isomerase assay.
  • the quantity of generated CLA was determined using a gas chromatography.
  • Lactobacillus candidates were inoculated into a MRS liquid medium containing LA, prior to culturing the mixture at 37° C. for 24-48 hours.
  • the cultured medium was extracted with heptadecanoic acid and a mixture of chloroform:methanol.
  • the extract was treated with sodium sulfate to remove moisture, and then evaporated.
  • 1N Sodium hydroxide (in methanol) was added to the prepared sample, prior to saponifying the sample at 100° C. for 15 minutes. Thereto 4% HCl (in methanol) was added to be methylated.
  • Hexane:water (1:1, v/v) were added to the methylated sample, and then mixed and centrifuged. An organic solvent fraction was taken to remove organic solvent using nitrogen gas, followed by dissolving the sample in hexane 1 mL.
  • CLA content within each sample before and after the removal of oxides was measured by gas chromatography (Hewlett Packard 5890 Series II GC) with a flame ionization detector (FID).
  • the used capillary column (DB FFAP capillary column) has a length of 30 m, an inner diameter of 0.25 ⁇ m, and a film thickness of 0.25 ⁇ m.
  • a GC was used under the following conditions: oven temperature (210° C.); detector temperature (270° C.); injector temperature (250° C.); carrier gas (Helium (1 mL/min)); split ratio (50:1); and sample injection (2 ⁇ l).
  • Each peak area was calculated using an integrator (3395, Hewlett Packard) linked with the GC.
  • CLA was identified, as compared with the retention time of a standard material.
  • Heptadecanoic acid was used as an internal standard material in order to measure CLA contents (Lin, T. Y. 2000. Conjugated linoleic acid concentration as affected by lactic cultures and additives, Food Chemistry 69. 27-31).
  • the isolated Lactobacillus strain produced both c9t11 and t10c12 isomers of CLA. If yield of t10c12 CLA with a body-fat reducing effect was indicated in terms of ppm, Lactobacillus rhamnosus Strain PL60 produced t10c12 CLA in an amount of 43.25 ppm and had more excellent productivity in comparison with the reported Lactobacillus reuteri and Lactobacillus fermentum that produced the CLA in amounts of 30 ppm and 28 ppm respectively.
  • CLA-producing Lactobacillus strains In order to identify CLA-producing Lactobacillus strains, it was confirmed whether they showed gram positive on a gram's staining and catalase negative or not.
  • Various biochemical and physiological tests were carried out using an API kit, and 16S rRNA sequence was analyzed and identified.
  • strains were identified by multiplex PCR assays using a group-specific primer.
  • the strains were cultured in a MRS medium at 30° C. or 37° C. for 24 hours. They were more than twice subcultured in a MRS broth, prior to isolating a colony from a MRS medium.
  • a suspension medium ample was opened to prepare a heavy suspension with very high turbidity using a cotton ball.
  • the prepared strain solution was dropped into the suspension medium 5 mL drop by drop till turbidity reached McFarland 2.
  • the API 50 CHL medium containing the strains was divided into tubes of a strip and cultured under the aerobic condition at 30° C. or 37° C. for 48 hours. If acid is generated, an API kit makes a medium yellowish by a bromocresol purple indicator within the medium. If color changes from purple to black in an Esculin test (Tube No. 25), it means a positive reaction.
  • Genomic DNA was isolated to amplify a 16S ribosomal DNA fragments thereof, prior to confirming the amplified DNA fragments by an electrophoresis.
  • DNA fragments were purified using a Qiagen PCR purification kit (Qiagen, Hilden, Germany) to be mixed with a reactant solution containing d-Rhodamine dye-labeling dd-NTP, prior to performing a direct sequencing to purify the obtained DNA using an ethanol/sodium acetate precipitation.
  • the purified DNA was dissolved in TSR (template suppression reagent) to be analyzed with an ABI prism 310 Genetic analyzer (PE Applied Biosystems, U.S.A). The analyzed sequence was identified using Genebank (http://www.ncbi.nlm.nih.gov/).
  • the DNA fragments obtained from the PL60 strain were compared with their DNA fragments after performing multiplex PCR assays (Song, Y., N. Kato, C. Liu, Y. Matsumiya, H. Kato, and K.
  • PCR reaction was carried out in a final amount of 300 using a mixture containing 1 ⁇ reaction buffer, dNTPs of 200 ⁇ M, Taq polymerase of 0.15 units, primers of 10 pmol (LU-5, CTA GCG GGT GCG ACT TTG; Lpar-4, GGC CAG CTA TGT ATT CAC TGA; Rha II, GCG ATG CGA ATT TCT ATT ATT), and DNA of 20 ng.
  • the PCR reaction comprised the following steps of: reacting the mixture repeating a cycle consisting of 20 seconds at 95° C., 2 minutes at 62° C., and 2 minutes at 74° C. 35 times; reacting the mixture at 72° C.
  • PCR resultant was electrophoresed in 1.5% agarose gel for 20 minutes using a 0.5 ⁇ TBE (0.045M tris-borate, 0.001M EDTA) buffer solution, followed by observing the patterns of the developed DNA fragments.
  • Lactobacillus rhamnosus strain and the PL60 strain produced DNA fragments of 113bp, whereas Lactobacillus paracasei ATCC 25302 produced DNA fragments with a size of 312 bp as shown in FIG. 4 . Consequently, the PL60 strain was identified as Lactobacillus rhamnosus .
  • CLA-producing Lactobacillus rhamnosus strain hasn't been reported yet.
  • the present invention reports CLA-producing Lactobacillus rhamnosus strain for the first time.
  • a MRS (DeMan-Rogosa-Sharpe) medium was used after adjusting pH to 7.0, 4.8, and 4.5 using 10N HCl.
  • the 0.D of pH 7.0 was diluted to 1/10 to measure and record an absorbance (Conway P L, Gorback S L, Goldin B R, 1987. Survival of lactic acid bacteria in the human stomach and adhesion to intestinal cells. J. Dairy Sci. 70:1-12).
  • ox-gall (OXOID) was added to a MRS (DeMan-Rogosa-Sharpe) medium in amounts of 0.125% and 0.25% to be sterilized.
  • the 0.D in 0% bile was diluted to 1/10 to measure and record an absorbance (Ibrahim S A, Bezkorovainy A. 1993. Survival of bifidobacteria in the presence of bile salt. J. Sci. Food Agric. 62: 351-354).
  • Lactobacillus rhamnosus Strain PL60 was adhered to Caco-2 cell lines derived from intestinal epidermal cells.
  • Caco-2 cell lines were cultured in a DMEM medium (pH 7.0) containing sodium bicarbonate 2.7 g/L, 20% (v/v) fetal bovine serum (FBS) and antibiotics antimicotics.
  • FBS fetal bovine serum
  • 3 ⁇ 10 5 Cells were inoculated into a medium of 2 mL in a petri dish of 30 mm to be cultured into a single layer. The medium was changed once every two days.
  • the cell single layer was twice rinsed with a phosphate buffered saline (PBS) solution of 2 mL, 6 days later.
  • PBS phosphate buffered saline
  • the Lactobacillus strain of 1 ⁇ 10 7 cells was suspended in a medium of 2 mL and added to a petri dish, prior to culturing the admixture at 37° C. under an 5% CO 2 -95% air atmosphere for 60-90 minutes.
  • the cells were twice rinsed with a sterilized PBS and fixed with methanol for 10 minutes. They were observed through an optical microscope after a gram's stain. 20 Fields were inspected under a 100-fold microscope for a quantitative analysis.
  • Lactobacillus rhamnosus Strain PL60 has excellent adhesion to the Caco-2 cells. If the number of adhered strains per a field was counted out of 20 fields to calculate an average number of adhered strains per a field, 59.29 ⁇ 5.33 Lactobacillus strains per a field were adhered. This means that more than 4000 of Lactobacillus strains per a petri dish were adhered to the cells and had better intestinal adhesion than the conventional Lactobacillus strains.
  • Lactobacillus rhamnosus Strain PL60 was orally administered in an amount of 10 10 CFU once a day for 8 days. The next day, feces were cultured in a MRS (with 1% bromo phenol blue, 30 ⁇ g/mL vancomycin) for 48 hours. All the similar colonies were examined by a gram's stain, subcultured, and purely isolated. Species-specific PCR assays were carried out using purely isolated colonies.
  • Lactobacillus rhamnosus Strain PL60 had been detected from one day to the six days after taking it and stopped an administration as soon as it was detected.
  • the detected Lactobacillus colony turned out to be Lactobacillus rhamnosus by a species-specific PCR assay ( FIG. 7 ).
  • FIG. 7 This proves that Lactobacillus rhamnosus Strain PL60 was adapted to the intestines.
  • FIG. 6 it was thought that judging by the fact that bacterial florae within the intestines got simpler after Lactobacillus rhamnosus Strain PL60 was administered, the Lactobacillus strain had an intestinal regulation.
  • Lactobacillus strains The safety test of Lactobacillus strains should be carried out for human dosage. For this, it was confirmed whether Lactobacillus strains produced toxic materials, such as ammonia, indole, hemolysin or like or not, and poisonous enzymes were present or not.
  • Lactobacillus rhamnosus Strain PL60 was inoculated into a sheep blood agar and cultured at 37° C. for 24 hours, only ⁇ -hemolysis was found, not ⁇ -hemolysis.
  • Lactobacillus rhamnosus Strain PL60 was inoculated into a slant medium made of a MRS gelatin medium (beef extract of 0.3 g, peptone of 0.5 g, gelatin of 12 g, and MRS broth of 100 mL) and cultured at 35° C. for 6 weeks. When it, together with a control, was cooled at 4° C. for 4 hours or so to examine gelatin liquefaction, it was thought that gelatinases were not present because a gelatin liquefaction wasn't observed.
  • MRS gelatin medium beef extract of 0.3 g, peptone of 0.5 g, gelatin of 12 g, and MRS broth of 100 mL
  • a urea agar medium (urea of 20 g, NaCl of 5 g, KH 2 PO 4 of 2 g, peptone of 1 g, glucose of 1 g, phenol of 12 mg, and distilled water of 100 mL) was filtered and sterilized, followed by dissolving agar of 15 g in distilled water of 900 mL to be wet-sterilized and mixed with the prepared urea agar medium to adjust a total volume to 1 L (pH 6.9). Thereto Lactobacillus rhamnosus Strain PL60 was inoculated and cultured at 37° C. for 12 hours or so, prior to observing color change of the medium. Because a yellow medium means negative, it was proved that Lactobacillus rhamnosus Strain PL60 didn't generate ammonia.
  • Lactobacillus rhamnosus Strain PL60 was inoculated into a MRS agar containing 0.1% tryptone and cultured for 18 hours or so. When thereto 5 drops of a Kovac's reagent (p-dimethylaminobenzaldehyde of 10 g, buthanol of 150 mL, and hydrocholic acid of 50 mL) were added, there was no color change. This means that indole wasn't produced.
  • a Kovac's reagent p-dimethylaminobenzaldehyde of 10 g, buthanol of 150 mL, and hydrocholic acid of 50 mL
  • Lactobacillus rhamnosus Strain PL60 was inoculated into a MRS medium containing 0.2% D,L-phenylalanine and cultured for 24 hours or like. After thereto letting 5-10 drops of 10% ferric chloride fall to flow down on a slant medium, a color change was observed within 1-5 minutes. In case of a positive reaction, the generated phenylpyiuvic acid was reacted with ferric chloride to make a medium green. Lactobacillus rhamnosus Strain PL60 showed a negative reaction.
  • Lactobacillus rhamnosus Strain PL60 cultured in a MRS liquid medium overnight was centrifuged at 3000 ⁇ g for 10 minutes to collect biomass, prior to sonicating the biomass for 5 minutes.
  • 4-Nitrobenzoic acid (final conc. 30 ⁇ g/mL) and trichloroacetic acid (final conc. 0.21%) were added to the supernatant and treated at 37° C. for 1 hour, followed by adding sodium nitrite (final conc. 0.007%) to be treated at room temperature for 20 minutes.
  • ammonium sulfamate final conc. 0.04% was added and treated at room temperature for 3 minutes.
  • NEDD N-(1-naphtyl)ethylenediamine dihydrdchloride
  • the cultured strain of 1 mL was mixed with Enterococcus faecalis CCARM 5510 of 1 mL, followed by filtering the mixture through a sterilized cellulose acetate filter to be washed with PPS (peptone physiological saline solution).
  • PPS peptone physiological saline solution
  • the filter paper was put on a non-selective agar medium and cultured at 37° C. for 16 hours. Biomass grown on the filter paper was washed with PPS of 2 mL and detached from the paper, prior to diluting the biomass to be inoculated into an Enterococcosal selective medium containing various antibiotics and cultured at 37° C.; for 24-48 hours. It was examined whether E. faecalis with an antibiotic resistance was present or not, but there was no E. faecalis with an antibiotic resistance in the culture. This means that the antibiotic resistance was not transferred.
  • LA As LA of high concentration inhibits the growth of bacteria themselves, LA can't be added to a medium in high concentration. In addition, in order to save LA spent on a medium LA concentration that could produce maximum CLA was found out.
  • Water-soluble LA ester was added to a skim milk medium and MRS medium for various concentrations and cultured overnight, followed by measuring the quantity of CLA generated within the media. For this, lipid within a medium was extracted and methylated, prior to measuring the quantity of generated CLA using a GC. To do this, heptadecanoic acid of 1000 ppm and chloroform:methanol (2:1) of 200 mL were added to a culture solution of 20 mL, followed by thereto adding glass beads to be strongly shaken for 5 minutes and homogenized for 5 minutes.
  • the admixture was centrifuged at 6000 rpm for 15 minutes (4° C.) and separated into two fractions.
  • An organic solvent fraction was treated with sodium sulfate to remove residual moisture, prior to evaporating organic solvent to be dried with nitrogen gas.
  • 1N Sodium hydroxide (methanol) 3 mL was added to the dried sample and saponified at 100° C. for 15 minutes.
  • a screw-capped tube treated with a Teflon tape was used and the cap was wrapped with a parafilm.
  • 4% HCl (methanol) 6 mL was added to be methylated for 20 minutes.
  • the methylated sample was mixed with hexane:water (1:1, v/v) of.
  • LA was added to a skim milk medium and MRS medium for a 0.1% concentration.
  • LA was added in three form of LA, LA salt, and LA and Tween-800 (0.2%) and cultured overnight, followed by confirming the CLA productivity of Lactobacillus rhamnosus Strain PL60.
  • lipid within a culture solution was extracted to be methylated, prior to determining the quantity of CLA by GC.
  • Emulsifier Addition Conditions upon Primary culture for Inducing CLA production
  • Lactobacillus rhamnosus Strain PL60 itself, or a starter strain or additive thereof, it was examined whether in case Lactobacillus rhamnosus Strain.
  • PL60 was cultured to produce products like lyophilized-dry powders, adding Tween-80 to increase solubility of LA was an efficient condition or not.
  • LA salt, LA and Tween-80 of 0.1%, LA and Tween-80 of 0.2%, and LA and Tween-80 of 0.5% were added to a medium on primary-culturing starter strains.
  • the primary-cultured Lactobacillus rhamnosus Strain PL60 was cultured in a CLA-producing medium (skim milk containing LA of 0.1%) to measure the quantity of the generated CLA.
  • fructose, sucrose, and lactose each was added to a skim milk containing 0.1% LA medium for a 6% concentration to measure a production of CLA.
  • CLA was produced most on adding fructose, followed by sucrose and lactose. When glucose was added, an effective CLA production was not observed.
  • a lyophilized Lactobacillus rhamnosus Strain PL60 that was cultured in a medium containing 0.1% LA and 0.2% Tween-80 using skim milk as an excipient was administered into a rat in a dose of 10 9 CFU/day and 10 7 CFU/day with giving a high-fat diet, followed by observing the change of body weight of a rat.
  • the first group was a group administered with a normal diet (Purina rodent chow #5057 (3.28 cal/g)
  • the second group was a group administered with a high-fat diet (Research diet 45% high fat diet D12451 (5.252 cal/g)
  • the third group was a control group administered with a high-fat diet and skim milk of an excipient
  • the fourth group was a group administered with a high-fat diet and Lactobacillus rhamnosus Strain PL60 in high concentration (10 9 CFU/day)
  • the fifth group was a group administered with a high-fat diet and Lactobacillus rhamnosus Strain PL60 in low concentration (10 7 CFU/day).
  • Table 9 represents the change of body weight of rats administered with Lactobacillus rhamnosus Strain PL60. According to Table 9, while a group administered with Lactobacillus rhamnosus Strain PL60 in high concentration, hardly showed a significant statistic on the 4th week, it had lower weight gain by more than 2 g on the 8th week, as compared with a control group ( FIG. 8 and FIG. 9 ).
  • a normal-diet group had an average weight of 24.7 g
  • a high fat-diet group had an average weight of 33.4 g
  • a skim-milk group had an average weight of 31.9 g
  • a group administered with Lactobacillus rhamnosus Strain PL60 in high concentration had an average weight of 26.9 g
  • a group administered with Lactobacillus rhamnosus Strain PL60 in low concentration had an average weight of 28.7 g.
  • the weight gain of the high-concentration group was lower than that of the high fat-diet group by 6.5 g, which was 19.5%.
  • the low-concentration group had a lower weight gain than the high fat-diet group by 4.7 g, which was 14%.
  • the high-concentration group and low-concentration group respectively showed lower weight gain by 5 g (15.7%) and 3.2 g (10%), as compared with a skim milk group. It was thought that the weight difference between a high fat diet group and a skim milk group was 1.5 g (4.5%), which was in the tolerance error range and was not a weight loss resulting from skim milk.
  • Lactobacillus rhamnosus Strain PL60 of the present invention has a body-fat reducing effect.
  • Said Lactobacillus strain can be directly used as body-fat reducing functional foods for preventing or treating all diseases resulting from obesity, or can be used as additives of body-fat reducing functional foods.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
US11/659,368 2004-08-16 2005-06-30 Lactobacillus Rhamnosus with Body-Fat Reducing Activity and the Foods Containing Them Abandoned US20080267932A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1020040064474A KR100686557B1 (ko) 2004-08-16 2004-08-16 체지방 저하 기능성 락토바실러스 람노서스와 이를 함유한 식품
KR10-2004-0064474 2004-08-16
PCT/KR2005/002066 WO2006019222A1 (fr) 2004-08-16 2005-06-30 Lactobacillus rhamnosus a activite de reduction de graisse corporelle et aliments les contenant

Publications (1)

Publication Number Publication Date
US20080267932A1 true US20080267932A1 (en) 2008-10-30

Family

ID=35907595

Family Applications (1)

Application Number Title Priority Date Filing Date
US11/659,368 Abandoned US20080267932A1 (en) 2004-08-16 2005-06-30 Lactobacillus Rhamnosus with Body-Fat Reducing Activity and the Foods Containing Them

Country Status (13)

Country Link
US (1) US20080267932A1 (fr)
EP (1) EP1789531B1 (fr)
JP (1) JP2008507991A (fr)
KR (1) KR100686557B1 (fr)
CN (1) CN101068918B (fr)
AT (1) ATE484574T1 (fr)
BR (1) BRPI0515227A (fr)
CA (1) CA2576106A1 (fr)
DE (1) DE602005024156D1 (fr)
DK (1) DK1789531T3 (fr)
HK (1) HK1116214A1 (fr)
MX (1) MX2007001863A (fr)
WO (1) WO2006019222A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109536415A (zh) * 2018-12-26 2019-03-29 汉臣氏（沈阳）儿童制品有限公司 一种鼠李糖乳杆菌及其应用
US20200061132A1 (en) * 2015-02-10 2020-02-27 Jinis Co., Ltd. Strain having ability to inhibit obesity and pharmaceutical composition containing same
CN111801413A (zh) * 2017-09-06 2020-10-20 韩国亿诺生物有限公司 鼠李糖乳杆菌lm1019菌株及包含其的用于预防及治疗肥胖或糖尿病的组合物
CN114381407A (zh) * 2022-02-07 2022-04-22 金华银河生物科技有限公司 一种鼠李糖乳杆菌r7970及其产物和应用
CN116904377A (zh) * 2023-09-13 2023-10-20 云南农业大学 一种高产共轭亚油酸菌株及降脂发酵乳和应用
CN117645965A (zh) * 2024-01-29 2024-03-05 潍坊康地恩生物科技有限公司 一株具有降解肠道吲哚、缓解慢性肾衰功能的鼠李糖乳酪杆菌

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1974734A1 (fr) † 2007-03-28 2008-10-01 Nestec S.A. Probiotiques pour la réduction du risque d'obésité
EP2022502A1 (fr) * 2007-08-10 2009-02-11 Nestec S.A. Lactobacillus rhamnosus et contrôle de poids
US20100284979A1 (en) * 2007-10-01 2010-11-11 University College Cork, National University Of Ireland, Cork Modulation of Tissue Fatty Acid Composition of a Host by Human Gut Bacteria
US8477143B2 (en) 2008-03-04 2013-07-02 Apple Inc. Buffers for display acceleration
CN101328470B (zh) * 2008-07-09 2010-06-09 扬州大学 具有降胆固醇及抑菌能力的鼠李糖乳杆菌grx10及其用途
EP2216036A1 (fr) 2009-02-10 2010-08-11 Nestec S.A. Lactobacillus rhamnosus NCC4007, mélange probiotique et contrôle de poids
EP2216035A1 (fr) * 2009-02-10 2010-08-11 Nestec S.A. Lactobacillus rhamnosus CNCM I-4096 et contrôle de poids
RU2453591C1 (ru) * 2011-04-21 2012-06-20 Общество с ограниченной ответственностью "Бифилюкс" Штамм lactobacillus rhamnosus, используемый для получения продукции, содержащей лактобактерии
EP2925333A1 (fr) 2012-11-12 2015-10-07 Compagnie Gervais Danone Souche de lactobacillus rhamnosus pour réduire l'accumulation de graisse corporelle
FR3004621B1 (fr) * 2013-04-19 2015-05-15 Gervais Danone Sa Souche de lactobacillus rhamnosus regulatrice du metabolisme lipidique
WO2014177667A1 (fr) * 2013-05-03 2014-11-06 Nestec S.A. Lachnospiraceae dans le microbiote de l'intestin et association avec le poids corporel
EP3202891B1 (fr) * 2014-09-30 2021-07-28 Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine Utilisation de bacteroides dans le traitement ou la prévention de l'obésité ou du diabète
CN104928208B (zh) * 2015-04-30 2020-04-10 江苏微康生物科技有限公司 一种植物乳杆菌Lp90及其筛选方法和应用
CN107949633B (zh) * 2015-08-12 2021-04-30 Cj第一制糖株式会社 鼠李糖乳杆菌、动物饲料及其组合物及无活性细胞生产法
KR102132827B1 (ko) 2015-10-21 2020-07-22 주식회사 단정바이오 락토바실러스 람노서스 비타피원 균주, 이를 이용한 칡 또는 대두 배아 발효물의 제조방법 및 이를 이용한 칡 또는 대두 배아 발효물
CN109251877B (zh) * 2018-10-13 2020-11-03 北京首佳利华科技有限公司 一种具有减脂等功能的纳豆芽孢杆菌Bn-SJLH001益生作用及其应用
CN110607255B (zh) * 2019-08-28 2022-06-10 华南理工大学 一种德氏乳杆菌及直投式德氏乳杆菌发酵剂的制备方法和应用
KR102591920B1 (ko) * 2020-06-26 2023-10-23 주식회사 메디오젠 체지방 감소 및 장 건강 증진 활성을 갖는 유산균 및 그의 용도
CN113088470A (zh) * 2021-04-14 2021-07-09 广东医科大学 一株鼠李糖乳杆菌L.rB16及其应用
KR102650558B1 (ko) * 2021-09-09 2024-03-26 주식회사 피엘비앤비 락토바실러스 람노서스 pl60을 유효성분으로 함유하는 염증질환 예방, 개선 또는 치료용 프로바이오틱스 조성물
CN114958694B (zh) * 2022-07-06 2023-05-02 福建生物工程职业技术学院 一种联产共轭亚油酸和γ-氨基丁酸的鼠李糖乳杆菌及应用
CN118638701A (zh) * 2024-08-19 2024-09-13 山东中科嘉亿生物工程有限公司 一种辅助改善节食后营养不良的鼠李糖乳杆菌jylr-173及其菌剂和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6060304A (en) * 1995-06-01 2000-05-09 Wisconsin Alumni Research Foundation Method of producing conjugated fatty acids

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1034788A1 (fr) * 1999-03-11 2000-09-13 Société des Produits Nestlé S.A. Souches de bacteries lactiques capables de prevenir la diarrhée
WO2000064854A1 (fr) * 1999-04-27 2000-11-02 Kabushiki Kaisha Yakult Honsha Esters d'acides gras conjugues
FI108730B (fi) * 1999-11-19 2002-03-15 Valio Oy Menetelmä konjugoidun linolihapon valmistamiseksi
CN1349795A (zh) * 2000-10-19 2002-05-22 珠海威尔发展有限公司 一种用于人体减肥的复方制剂及其应用
AU2003221135A1 (en) * 2002-04-12 2003-10-27 Chebigen Inc. New strains capable of producing conjugated linoleic acid, capsulated composition comprising them, and the preparation methods thereof
EP1500706B1 (fr) 2002-04-12 2009-10-14 Kabushiki Kaisha Yakult Honsha Procede de production d'acide gras conjugue et aliment /boisson obtenus grace a ce procede
KR100470460B1 (ko) * 2003-01-09 2005-02-05 대한민국 씨엘에이를 생산하는 락토바실러스 퍼멘텀 및 이를 이용한다량의 씨엘에이를 함유하는 배양액 제조방법

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6060304A (en) * 1995-06-01 2000-05-09 Wisconsin Alumni Research Foundation Method of producing conjugated fatty acids

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200061132A1 (en) * 2015-02-10 2020-02-27 Jinis Co., Ltd. Strain having ability to inhibit obesity and pharmaceutical composition containing same
US11273188B2 (en) * 2015-02-10 2022-03-15 Microbiotica Gmbh Strain having ability to inhibit obesity and pharmaceutical composition containing same
CN111801413A (zh) * 2017-09-06 2020-10-20 韩国亿诺生物有限公司 鼠李糖乳杆菌lm1019菌株及包含其的用于预防及治疗肥胖或糖尿病的组合物
CN109536415A (zh) * 2018-12-26 2019-03-29 汉臣氏（沈阳）儿童制品有限公司 一种鼠李糖乳杆菌及其应用
CN114381407A (zh) * 2022-02-07 2022-04-22 金华银河生物科技有限公司 一种鼠李糖乳杆菌r7970及其产物和应用
CN116904377A (zh) * 2023-09-13 2023-10-20 云南农业大学 一种高产共轭亚油酸菌株及降脂发酵乳和应用
CN117645965A (zh) * 2024-01-29 2024-03-05 潍坊康地恩生物科技有限公司 一株具有降解肠道吲哚、缓解慢性肾衰功能的鼠李糖乳酪杆菌

Also Published As

Publication number Publication date
EP1789531B1 (fr) 2010-10-13
MX2007001863A (es) 2007-10-03
CA2576106A1 (fr) 2006-02-23
DE602005024156D1 (de) 2010-11-25
KR100686557B1 (ko) 2007-02-23
ATE484574T1 (de) 2010-10-15
EP1789531A1 (fr) 2007-05-30
BRPI0515227A (pt) 2008-07-15
CN101068918A (zh) 2007-11-07
EP1789531A4 (fr) 2008-03-19
HK1116214A1 (en) 2008-12-19
DK1789531T3 (da) 2011-01-10
CN101068918B (zh) 2010-05-26
KR20060016048A (ko) 2006-02-21
WO2006019222A1 (fr) 2006-02-23
JP2008507991A (ja) 2008-03-21

Similar Documents

Publication Publication Date Title
US20080267932A1 (en) Lactobacillus Rhamnosus with Body-Fat Reducing Activity and the Foods Containing Them
US20080057044A1 (en) Lactobacillus Plantarum with Body-Fat Reducing Activity and the Foods Containing Them
Nath et al. In vitro screening of probiotic properties of Lactobacillus plantarum isolated from fermented milk product
JP4022777B2 (ja) コレステロールを低下および同化する能力を有する酸および胆汁酸塩耐性のＬａｃｔｏｂａｃｉｌｌｕｓ分離株
EP1424075B1 (fr) Lactobacillus resistant aux acide, et sel biliaire, et capable d'assimiler et baisser le taux de cholesterol
Kim et al. Characterization of lactic bacterial strains isolated from raw milk
KR100715730B1 (ko) 유해 병원성 미생물에 대한 항균활성을 갖는 신규비피도박테리움 롱검 ａ24
KR100443080B1 (ko) 콜레스테롤 저하능을 갖는 스트렙토코커스 페시움 균주
KR100871904B1 (ko) 락토바실러스 애시도필러스 ｋｃｎｕ
AU2015201076B2 (en) Lipid metabolism-improving agent
KR20220007660A (ko) 프럭토필릭 락트산 생산 박테리아
Shobharani Isolation and characterization of a native isolate of Leuconostoc for functional attributes

Legal Events

Date Code Title Description
AS Assignment

Owner name: CJ CORP., KOREA, REPUBLIC OF

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LEE, YEON-HEE;PAEK, KYUNG-SOO;SOHN, KENNY;AND OTHERS;REEL/FRAME:018895/0848

Effective date: 20070110

Owner name: PL BIO CO., LTD., KOREA, REPUBLIC OF

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LEE, YEON-HEE;PAEK, KYUNG-SOO;SOHN, KENNY;AND OTHERS;REEL/FRAME:018895/0848

Effective date: 20070110

AS Assignment

Owner name: CJ CHEILJEDANG CORP., KOREA, REPUBLIC OF

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CJ CORP.;REEL/FRAME:020489/0538

Effective date: 20080111

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION